What conditions are treated with radioimmunotherapy?
There are two RIT agents approved by the U.S. Food and Drug Administration (FDA): Zevalin and Bexxar. Both of these are used to treat patients with B-cell Follicular non-Hodgkin Lymphoma (NHL) that has not responded to Chemotherapy treatment, although these can be used in some other types of lymphomas or scenarios as a part of the treatment for a patient’s Lymphoma. Zevalin, consists of a radioactive molecule Yttrium-90 (Y-90) combined with the monoclonal antibody ibritumomab tiuxetan; Bexxar, is a compound consisting of Iodine-131 (I-131) and tositumomab. Currently, only Zevalin (Y-90 Ibritumomab tiuxetan) is available on the market.